News
7h
Investor's Business Daily on MSNHims & Hers Health Closes In On Buy Point As Earnings LoomHims stock is climbing back from a steep drop within a base. Shares have climbed nearly 29% during the month and outperformed ...
11h
Zacks Investment Research on MSNHims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should KnowHims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...
Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
Hims & Hers Health, Inc. HIMS has seen a surge in retail investor interest, which positions it as one of the most ...
Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results